

**UNIVERSITATEA TITU MAIORESCU BUCUREȘTI**  
**FACULTATEA DE MEDICINĂ**  
SPITALUL CLINIC COLENTINA – SECȚIA HEMATOLOGIE I

# **LISTA COMPLETĂ A LUCRĂRILOR ȘTIINȚIFICE**

**Conf. univ. dr. MIHAELA ANDREESCU**

Medic Primar Hematologie  
Șef Secție Hematologie I, Spitalul Clinic Colentina

**ORCID:** [0000-0003-0532-7929](https://orcid.org/0000-0003-0532-7929)

**ResearcherID:** [AAB-7550-2021](https://pubs.acs.org/doi/10.26434/chemrxiv-2021-aab-7550)

# LISTA COMPLETĂ DE LUCRĂRI ȘTIINȚIFICE

Conf. univ. dr. MIHAELA ANDREESCU

Universitatea Titu Maiorescu București | Spitalul Clinic Colentina

## METRICI SCIENTOMETRICE

H-index (WOS)	8	Total citări (WOS)	197
WOS Core Collection	71	Total articole in care se fac citari	175
Total WOS (toate bazele)	101		

ORCID: 0000-0003-0532-7929

ResearcherID AAB-7550-2021

## SECȚIUNEA A: ARTICOLE WOS - AUTOR PRINCIPAL (15 articole)

(singur autor sau primul autor în lista de autori)

Nr.	Titlu / Autori / Jurnal / DOI	IF	Q	Cit	WOS ID
<b>2025</b>					
1	<b>A Review of Immunological Evaluation of Patients with Recurrent Spontaneous Abortion (RSA)</b> <i>Andreescu M, Tanase A, Andreescu B, Moldovan C</i> International Journal of Molecular Sciences, 2025; 26(2): 785 DOI: <a href="https://doi.org/10.3390/IJMS26020785">10.3390/IJMS26020785</a>	4.9	Q1	7	WOS:001404384400001
2	<b>IL-4 and Brentuximab Vedotin in Mycosis Fungoides: A Perspective on Potential Therapeutic Interactions and Future Research Directions</b> <i>Andreescu M, Tudorache SI, Olteanu SLG, Andreescu B</i> Current Issues in Molecular Biology, 2025; 47(8): 586 DOI: <a href="https://doi.org/10.3390/CIMB47080586">10.3390/CIMB47080586</a>	3.0	Q2	0	WOS:001557364000001
<b>2024</b>					
3	<b>Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies</b> <i>Andreescu M</i> Cureus, 2024; 16(1): e51662 DOI: <a href="https://doi.org/10.7759/cureus.51662">10.7759/cureus.51662</a>	1.3	Q2	4	WOS:001166048400005
4	<b>Correlation Between Maternal-Fetus Interface and Placenta-Mediated Complications</b> <i>Andreescu M</i> Cureus, 2024; 16(6): e62457 DOI: <a href="https://doi.org/10.7759/cureus.62457">10.7759/cureus.62457</a>	1.3	Q2	3	WOS:001255974100030
5	<b>A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery</b> <i>Andreescu M, Andreescu B</i> Cureus, 2024; 16(3): e56008 DOI: <a href="https://doi.org/10.7759/cureus.56008">10.7759/cureus.56008</a>	1.3	Q2	3	WOS:001203209500024
6	<b>COVID-19-Associated Rhinocerebral Mucormycosis - Mixed-Method Systematic Review</b> <i>Andreescu M, Moldovan C, Lespezeanu DA, Mocanu AI, Schipor MA, Mocanu H</i> Infection and Drug Resistance, 2024; 17: 387-402 DOI: <a href="https://doi.org/10.2147/IDR.S445458">10.2147/IDR.S445458</a>	2.9	Q2	2	WOS:001155928500001
7	<b>Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy</b> <i>Andreescu M, Andreescu B</i> Cureus, 2024; 16(1): e52737 DOI: <a href="https://doi.org/10.7759/cureus.52737">10.7759/cureus.52737</a>	1.3	Q2	0	WOS:001156009200007
<b>2023</b>					
8	<b>Recurrent Abortion and the Involvement of KIR Genes, Activated T Cells, NK Abnormalities, and Cytokine Profiles</b> <i>Andreescu M, Frincu F, Plotogea M, Mehedintu C</i> Journal of Clinical Medicine, 2023; 12(4): 1355 DOI: <a href="https://doi.org/10.3390/jcm12041355">10.3390/jcm12041355</a>	3.0	Q1	16	WOS:000938520800001
9	<b>The impact of the use of immunosuppressive treatment after an embryo transfer in increasing the rate of live birth</b> <i>Andreescu M</i>	3.1	Q1	12	WOS:001025662600001

	Frontiers in Medicine, 2023; 10: 1167876 DOI: 10.3389/fmed.2023.1167876				
10	<b>Molecular Insights Into the Role of Gut Microbiota in Antibiotic Therapy Selection and Resistance Mitigation</b> <i>Andrescu M</i> Cureus, 2023; 15(12): e50318 DOI: 10.7759/cureus.50318	1.3	Q3	9	WOS:001126866900024
11	<b>Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies</b> <i>Andrescu M</i> Life, 2023; 13(6): 1272 DOI: 10.3390/life13061272	3.2	Q1	4	WOS:001014961700001
12	<b>Recent Advances in Serum Biomarkers for Cardiological Risk Stratification in Hematological Malignancies</b> <i>Andrescu M</i> Cureus, 2023; 15(11): e49696 DOI: 10.7759/cureus.49696	1.0	Q3	2	WOS:001122720400033
13	<b>The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutical targets</b> <i>Andrescu M</i> Frontiers in Hematology, 2023; 2: 1191178 DOI: 10.3389/frhem.2023.1191178	0.6	Q4	4	WOS:001574438800001
14	<b>Assessment of Impact of HLA-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy in CLL</b> <i>Andrescu M, Berbec N, Tanase AD</i> Journal of Clinical Medicine, 2023; 12(7): 2731 DOI: 10.3390/jcm12072731	3.0	Q1	2	WOS:000969661600001
15	<b>Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin's lymphoma</b> <i>Andrescu M, Zurac S, Lacatusu A, Tudor AT, Ilie N, Tirlea LG, et al.</i> Revista Romana de Medicina de Laborator, 2023; 31(1): 59-64 DOI: 10.2478/rrlm-2023-0007	0.5	Q4	0	WOS:000934916900007

## SECȚIUNEA B: ARTICOLE WOS - CO-AUTOR (12 articole)

(contribuție în echipe de cercetare)

Nr.	Titlu / Autori / Jurnal / DOI	IF	Q	Cit	WOS ID
<b>2025</b>					
1	<b>Managing HIV-Associated Hodgkin Lymphoma During the COVID-19 Pandemic</b> <i>Padurariu-Covit MD, Andrescu M, et al.</i> Viruses, 2025; 17(3): 404 DOI: 10.3390/v17030404	3.5	Q2	2	WOS:001453142300001
2	<b>CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions</b> <i>Padurariu-Covit MD, Georgescu C, ... Andrescu M, et al.</i> Viruses, 2025; 17(12): 1615 DOI: 10.3390/v17121615	3.5	Q2	0	WOS:001647500500001
3	<b>Intraventricular mass in a 52-year-old woman</b> <i>Brehar FM, Patrascan AM, Andrescu M, et al.</i> Brain Pathology, 2025; 35(3): e70003 DOI: 10.1111/bpa.70003	6.2	Q1	0	WOS:001521288100004
<b>2024</b>					
4	<b>Women's Sexual Dysfunctions Following Stem Cell Transplant</b> <i>Plotogea M, Zgura A, et al., Andrescu M, et al.</i> Life, 2024; 14(1): 35 DOI: 10.3390/life14010035	3.2	Q1	3	WOS:001151531800001
<b>2021</b>					
5	<b>Evaluation of the impact of Covid-19 infection on the evolution of patients with acute leukaemia</b> <i>Omer M, Vladareanu AM, et al., Andrescu M</i> Revista Romana de Medicina de Laborator, 2021; 29(4): 377-384 DOI: 10.2478/rrlm-2021-0032	0.8	Q4	1	WOS:000710808400003
<b>2020</b>					
6	<b>Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience</b> <i>Tanase AD, Colita A, et al., Andrescu M, et al.</i> Journal of Clinical Medicine, 2020; 9(8): 2417 DOI: 10.3390/jcm9082417	4.24	Q1	14	WOS:000564674800001
<b>2018</b>					
7	<b>MECOM, HBS1L-MYB, THRB-ARB, JAK2 and TERT polymorphism in MPN: study on 939 patients</b>	2.16	Q1	31	WOS:000417527300026

	<i>Trifa AP, Banescu C, et al., Andreescu M, et al.</i> American Journal of Hematology, 2018; 93(1): 100-106 DOI: <a href="https://doi.org/10.1002/ajh.24946">10.1002/ajh.24946</a>				
8	<b>Modest contribution of JAK2 V617F allele burden to major thrombosis in PV and ET</b> <i>Trifa AP, Banescu C, et al., Andreescu M, Popp RA</i> Blood Cells, Molecules and Diseases, 2018; 73: 45-46	1.7	Q2	6	WOS:000445530600008
<b>2016</b>					
9	<b>TERT rs2736100 and JAK2 46/1 haplotype contribute to JAK2 V617F and CALR MPN - 529 patients</b> <i>Trifa AP, Banescu C, Tevet M (Andreescu M), et al.</i> British Journal of Haematology, 2016; 174(2): 218-226 DOI: <a href="https://doi.org/10.1111/bjh.14041">10.1111/bjh.14041</a>	5.67	Q1	33	WOS:000383773700004
10	<b>Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C&gt;T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms</b> <i>Trifa AP, Banescu C, et al., Tevet M (Andreescu M), et al.</i> Hematology, 2016; 21(9): 520-525 DOI: <a href="https://doi.org/10.1080/10245332.2016.1163889">10.1080/10245332.2016.1163889</a>	2.27	Q3	8	WOS:000383392300003
<b>2015</b>					
11	<b>CALR versus JAK2 mutated essential thrombocythaemia - 141 patients</b> <i>Trifa AP, Popp RA, et al., Tevet M (Andreescu M), et al.</i> British Journal of Haematology, 2015; 168(1): 151-153 DOI: <a href="https://doi.org/10.1111/bjh.13076">10.1111/bjh.13076</a>	4.97	Q1	16	WOS:000346151600021
12	<b>Multiple Intestinal Lymphoma</b> <i>Mastalier B, Deaconescu V, et al., Tevet M (Andreescu M), Botezatu C</i> Romanian Journal of Internal Medicine, 2015; 53(1): 73-78 DOI: <a href="https://doi.org/10.1515/rjim-2015-0010">10.1515/rjim-2015-0010</a>	1.40	Q4	8	WOS:000217653700010

## SECȚIUNEA C: Lucrări la conferințe (poster/comunicare/abstract) publicate ca abstracte în suplimentele revistelor indexate WOS (42 lucrări)

Nr.	Titlu / Autori / Jurnal / DOI	IF	Q	Cit	WOS ID
1	<b>Evaluation of Prognostic Factors in Secondary Acute Leukemia Patients</b> <i>Omer M, Popov VM, Bumbea H, Andreescu M, et al.</i> Blood, 2024; 144: 6141 DOI: <a href="https://doi.org/10.1182/blood-2024-207824">10.1182/blood-2024-207824</a>	21.0	Q1	0	WOS:001416740700024
2	<b>A Primary Pulmonary Determination-A Rare Form of Marginal B-Cell Lymphoma</b> <i>Popov VM, Voicu M, et al., Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S221 DOI: <a href="https://doi.org/10.1016/S2152-2650(24)01556-8">10.1016/S2152-2650(24)01556-8</a>	2.7	Q3	0	OS:001315579604190
3	<b>Extramedullary Multiple Myeloma - Retroperitoneal Mass and Cholestatic Syndrome</b> <i>Popov VM, et al., Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S537 DOI: <a href="https://doi.org/10.1016/S2152-2650(24)01644-6">10.1016/S2152-2650(24)01644-6</a>	2.7	Q3	0	WOS:001315579605082
4	<b>Complex Clonal Evolution in Advanced Myelofibrosis</b> <i>Bacanu M, Popov VM, et al., Andreescu M, Omer M</i> Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S416 DOI: <a href="https://doi.org/10.1016/S2152-2650(24)01402-2">10.1016/S2152-2650(24)01402-2</a>	2.7	Q3	0	WOS:001315579604036
5	<b>Particularities of Evolution in Acute Leukemia Patients With History of Neoplasms</b> <i>Omer M, Popov VM, Andreescu M, et al.</i> Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S319-S320 DOI: <a href="https://doi.org/10.1016/S2152-2650(24)01211-4">10.1016/S2152-2650(24)01211-4</a>	2.7	Q3	0	WOS:001315579603042
6	<b>COVID-19-Trigger for Chronic Myeloid Leukemia Evolution?</b> <i>Popov V, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2023; 23: S333 DOI: <a href="https://doi.org/10.1016/S2152-2650(23)01124-2">10.1016/S2152-2650(23)01124-2</a>	2.7	Q3	0	WOS:001062479600257
7	<b>Is COVID-19 Infection a Trigger for Progression of CLL?</b> <i>Popov V, Bumbea H, Andreescu M, et al.</i> Clinical Lymphoma Myeloma and Leukemia, 2022; 22: S140/S260 doi: <a href="https://doi.org/10.1016/S2152-2650(22)01313-1">10.1016/S2152-2650(22)01313-1</a>	2.8	Q3	2	WOS:000897948100192
8	<b>The importance of the long Covid-19 in the evolution of patients with neoplasms</b> <i>Popov V, Andreescu M, et al.</i> Journal of Clinical Oncology, 2022; 40(16_suppl): e18647 DOI: <a href="https://doi.org/10.1200/JCO.2022.40.16_suppl.e18647">10.1200/JCO.2022.40.16_suppl.e18647</a>	50.7	Q1	0	WOS:000863680303796

Nr.	Titlu / Autori / Jurnal / DOI	IF	Q	Cit	WOS ID
9	<b>The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center</b> <i>Popov VM, Iliescu L, et al., Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2021; 21: S285-S286 doi: <a href="https://doi.org/10.1016/S2152-2650(21)01685-2">10.1016/S2152-2650(21)01685-2</a>	3.2	Q3	1	WOS:000691910500124
10	<b>Assessment of Hematologic and Coagulation Parameters As Predictive Value in COVID-19 with Unfavourable Evolution</b> <i>Popov VM, Iliescu L, et al., Andreescu M, Bumbea H</i> Blood, 2020; 136(Suppl 1): 13 DOI <a href="https://doi.org/10.1182/blood-2020-134153">10.1182/blood-2020-134153</a>	22.1	Q1	0	WOS:000607547206012
11	<b>Assessment of clinical evolution of COVID-19 and neoplastic malignancies patients</b> <i>Popov V, Andreescu M, et al.</i> American Journal of Hematology, 2020; 95(S2): S26-S27 <a href="https://doi.org/10.1002/ajh.26005">https://doi.org/10.1002/ajh.26005</a>	10.0	Q1	0	WOS:000577607300033
12	<b>The Prolonged Positivity of SARSCoV-2 RNA in Chronic Lymphocytic Leukemia Patients</b> <i>Popov V, Andreescu M, et al.</i> Clinical Lymphoma Myeloma and Leukemia, 2020; 20: S228 DOI : <a href="https://doi.org/10.1016/S2152-2650(20)30804-1">10.1016/S2152-2650(20)30804-1</a>	2.36	Q3	0	WOS:000564055100176
13	<b>The Evaluation of Haematological and Biochemistry Parameters in COVID-19 Patients as a Predictive Factor for Unfavourable Evolution</b> <i>Popov V, Iliescu L, Andreescu M, et al.</i> Clinical Lymphoma Myeloma and Leukemia, 2020; 20: S217 <a href="https://doi.org/10.1016/S2152-2650(20)30784-9">https://doi.org/10.1016/S2152-2650(20)30784-9</a>	2.36	Q3	0	WOS:000564055100155
14	<b>Results from Treatment of a Large Cohort of ATL Patients from Romania</b> <i>Bumbea H, Marçais A, et al., Andreescu M, et al.</i> Blood, 2019; 134(Suppl 1): 5288 <a href="https://doi.org/10.1182/blood-2019-126434">https://doi.org/10.1182/blood-2019-126434</a>	17.5	Q1	4	WOS:000577164606007
15	<b>The Importance of CD36 Expression in Thrombotic Risk in MPN</b> <i>Popov VM, Omer M, Trifa AP, et al., Andreescu M, Bumbea H</i> Blood, 2018; 132(Suppl 1): 4989 <a href="https://doi.org/10.1182/blood-2018-99-115349">https://doi.org/10.1182/blood-2018-99-115349</a>	15.1	Q1	2	WOS:000454842805263
16	<b>Evaluation of Oxidative Status and Platelet Membrane Function in Chronic MPN</b> <i>Popov V, Oktaviani CM, et al., Andreescu M, Bumbea H</i> International Journal of Laboratory Hematology, 2018; 40: 117	2.1	Q2	0	WOS: 000444677800217
17	<b>Assessment of Changes of Membrane Properties and Platelets Function in CML</b> <i>Popov V, Viadareanu AM, et al., Andreescu M, et al., Bumbea H</i> Blood, 2017; 130(Suppl 1): 4846 <a href="https://doi.org/10.1182/blood.V130.Suppl_1.4846.4846">https://doi.org/10.1182/blood.V130.Suppl_1.4846.4846</a>	13.2	Q1	0	WOS: 000432419705023
18	<b>Aggressive paraneoplastic encephalo-myelo-polyradiculoneuritis with anaplastic lymphoma</b> <i>Gaciu GC, et al., Andreescu M, et al.</i> European Journal of Neurology, 2017; 24(Suppl S1): 440	4.0	Q1	0	WOS: 000405530100738
19	<b>Genomic abnormalities in acute myeloid leukemia with normal karyotype</b> <i>Arghir A, Papuc SM, et al., Andreescu M, et al., Bumbea H</i> Molecular Cytogenetics, 2017; 10(Suppl 1): 23 <a href="https://doi.org/10.1186/s13039-017-0319-3">https://doi.org/10.1186/s13039-017-0319-3</a>	1.2	Q3	0	WOS: 000410864800150
20	<b>Platelet Membrane Fluidity and Oxidative Stress in Thrombotic Complications in MPN</b> <i>Popov VM, Andreescu M, Omer M, Trifa AP, et al.</i> Haematologica, 2017; 102(Suppl 2): 649-650 <a href="https://haematologica.org/article/view/8147">https://haematologica.org/article/view/8147</a>	9.1	Q1	0	WOS: 000404127005105
21	<b>Thrombotic Complications in Hematologic Malignancies</b> <i>Popescu M, Georgescu D, et al., Tevet M (Andreescu M), et al.</i> Haematologica, 2016; 101(Suppl 1): 871-872 <a href="https://haematologica.org/article/view/7762">https://haematologica.org/article/view/7762</a>	7.7	Q1	0	WOS: 000379484603337
22	<b>THE IMPORTANCE OF OXIDATIVE STRESS IN ABNORMALITIES OF PLATELET FUNCTION. THE RETROSPECTIVE STUDY IN CHRONIC MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME PATIENTS</b>	2.3	Q1	0	WOS: 000376766300232

Nr.	Titlu / Autori / Jurnal / DOI	IF	Q	Cit	WOS ID
	Popov V, Iordache M, Vladareanu AM, Tevet M (Andreescu M) Thrombosis Research, 2016; 141(Suppl 1): S81 <a href="https://medleague-thrombosis.org/wp-content/uploads/2021/05/EMLTD2016-Abstracts.pdf">https://medleague-thrombosis.org/wp-content/uploads/2021/05/EMLTD2016-Abstracts.pdf</a>				
23	<b>Hyper eosinophilic syndromes FIP1L1/PDGFR A fusion gene NEGATIVE</b> Georgescu D, et al., Tevet M (Andreescu M), et al. British Journal of Haematology, 2016; 173(Suppl S1): 175-176	5.4	Q1	0	WOS: 000374543900433
24	<b>Hematological malignancies in HIV/AIDS</b> Georgescu DG, Tevet MT (Andreescu M), et al. British Journal of Haematology, 2016; 173(Suppl S1): 173-174	5.4	Q1	0	WOS: 000374543900427
25	<b>Efficacy and tolerability of ruxolitinib in myelofibrosis patients</b> Popov VM, Tevet M (Andreescu M), et al. British Journal of Haematology, 2016; 173(Suppl S1): 129	5.4	Q1	0	WOS: 000374543900313
26	<b>Acute myeloid leukemia in a 19-year-old patient treated for osteosarcoma</b> Dragan C, Murat M, Georgescu D, Tevet M (Andreescu M), Mihai F Bone Marrow Transplantation, 2016; 51: S599 <a href="https://doi.org/10.1038/bmt.2016.56">https://doi.org/10.1038/bmt.2016.56</a>	3.6	Q2	0	WOS: 000373357601551
27	<b>THE EXPERIENCE OF A SINGLE CENTER OF HEMATOLOGY IN THE TREATMENT WITH HYPOMETHYLATING AGENTS</b> Georgescu D, Popescu M, Tevet M (Andreescu M), et al. Leukemia Research, 2015; 39(S1): S95-S96 <a href="https://doi.org/10.1016/S0145-2126(15)30192-2">https://doi.org/10.1016/S0145-2126(15)30192-2</a>	2.6	Q2	0	WOS: 000373183500192
28	<b>Variation and distribution of mast cells in lymphoid lesions</b> Cioplea MD, Zurac S, et al., Tevet M (Andreescu M), et al. Virchows Archiv, 2014; 465(Suppl 1): S278 DOI: <a href="https://doi.org/10.1007/s00428-014-1618-2">10.1007/s00428-014-1618-2</a>	2.7	Q2	0	WOS: 000344386802079
29	<b>Clinical significance of JAK2 mutation in chronic MPN - hemorrhagic risk</b> Tevet M (Andreescu M), Lupu AR, Saguna C, et al. Haematologica, 2012; 97(Suppl 1): 636 <a href="https://haematologica.org/issue/view/242">https://haematologica.org/issue/view/242</a>	5.9	Q1	0	WOS: 000496830406133
30	<b>The role of JAK2-V617F mutation in leukemic transformation of MPN</b> Tevet M (Andreescu M), Lupu AR, Saguna C, et al. Haematologica, 2012; 97(Suppl 1): 633 <a href="https://haematologica.org/issue/view/242">https://haematologica.org/issue/view/242</a>	5.9	Q1	0	WOS: 000496830406124
31	<b>Complete Response in Heavily Pretreated Refractory Mantle Cell Lymphoma After Bendamustine and Glofitamab: A Paradigm Shift in Immunotherapy Sequencing</b> Malenda AD, Bacanu M, Pirvu E, Grasu D, Vasile AC, Popov VM, Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S281/S851 <a href="https://doi.org/10.1016/S2152-2650(25)02472-3">https://doi.org/10.1016/S2152-2650(25)02472-3</a>	2.7	Q3	0	WOS:001606048700040
32	<b>Clinical Challenges and Management of Indolent Non-Hodgkin Lymphomas in Patients With Autoimmune Diseases: Integrating Hematologic and Immunologic Considerations</b> Herdea MS, Ionescu AS, Popescu G, Patrinoiu O, Popescu M, Popov V, Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S276/S826-S827 <a href="https://doi.org/10.1016/S2152-2650(25)02428-0">https://doi.org/10.1016/S2152-2650(25)02428-0</a>	2.7	Q3	0	WOS:001607063000093
33	<b>POEMS Syndrome in the Post-Pandemic Era: A Rare Disease With Rising Incidence - Experience From a Single Romanian Center</b> Tirlea LG, Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S296/S922-S923 <a href="https://doi.org/10.1016/S2152-2650(25)02608-4">https://doi.org/10.1016/S2152-2650(25)02608-4</a>	2.7	Q3	0	WOS:001606059100058
34	<b>CD20-Negative Double-Expressor DLBCL: A Case of Aggressive, Chemorefractory Disease With Limited Therapeutic Options</b> Grasu D, Pirvu E, Bacanu M, Malenda D, Vasile A, Popov V, Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S259/S751 DOI: <a href="https://doi.org/10.1016/S2152-2650(25)02287-6">10.1016/S2152-2650(25)02287-6</a>	2.7	Q3	0	WOS:001606311300061
35	<b>VEGF-Refractory Castleman-Variant POEMS Without Monoclonal Protein: Navigating Therapeutic and Access Gaps in a Rare Clinical Entity</b> Olteanu SLG, Tirlea LG, Andreescu M, Popov V	2.7	Q3	0	WOS:001606059100059

Nr.	Titlu / Autori / Jurnal / DOI	IF	Q	Cit	WOS ID
	Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S296/S922 DOI: <a href="https://doi.org/10.1016/S2152-2650(25)02607-2">10.1016/S2152-2650(25)02607-2</a>				
36	<b>When First Impressions Are Misleading: Imaging and Histopathology in the Reclassification of Indolent Lymphoma</b> <i>Voicu MC, Popov VM, Panait A, Petraru AM, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S809 DOI: <a href="https://doi.org/10.1016/S2152-2650(25)02395-X">10.1016/S2152-2650(25)02395-X</a>	2.7	Q3	0	WOS:001607063000059
37	<b>Case Report: Complex Management of Relapsed/Refractory Classical Hodgkin Lymphoma Complicated by Pregnancy and Chronic Pulmonary Aspergillosis</b> <i>Grasu D, Pirvu E, Malenda D, Bacanu M, Vasile A, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S707 <a href="https://doi.org/10.1016/S2152-2650(25)02200-1">https://doi.org/10.1016/S2152-2650(25)02200-1</a>	2.7	Q3	0	WOS:001605514900078
38	<b>Ocular Adnexal Involvement in Mantle Cell Lymphoma: An Unusual Case Report Unmasking Systemic Disease and Diagnostic Pitfalls</b> <i>Bacanu M, Omer M, Popov V, Pirvu E, Grasu D, Malenda AD, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S855 <a href="https://doi.org/10.1016/S2152-2650(25)02479-6">https://doi.org/10.1016/S2152-2650(25)02479-6</a>	2.7	Q3	0	WOS:001606048700047
39	<b>MDS-RS Evolving From Hereditary Sideroblastic Anemia: A Diagnostically Challenging Case With Multisystem Involvement</b> <i>Cernat MR, Vasile AC, Malenda DA, Grasu D, Pirvu E, Olteanu SL, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S624-S625 <a href="https://doi.org/10.1016/S2152-2650(25)02048-8">https://doi.org/10.1016/S2152-2650(25)02048-8</a>	2.7	Q3	0	WOS:001605540100031
40	<b>Oncological and Cytogenetic Duality: Simultaneous Acute Lymphoblastic Leukaemia and Renal Neoplasm in a Clinical Case</b> <i>Ionescu AS, Herdea MS, Popov VM, Ofiteru GC, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S352-S353 DOI: <a href="https://doi.org/10.1016/S2152-2650(25)01532-0">10.1016/S2152-2650(25)01532-0</a>	2.7	Q3	0	WOS:001606305100040
41	<b>Sequential Multilineage Hematologic Malignancies: A Case of Marginal Zone B-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Chronic Myeloid Leukemia</b> <i>Malenda AD, Bacanu M, Pirvu E, Grasu D, Vasile AC, Popov VM, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S218/S570 <a href="https://doi.org/10.1016/S2152-2650(25)01944-5">https://doi.org/10.1016/S2152-2650(25)01944-5</a>	2.7	Q3	0	WOS:001606303900043
42	<b>The Successful Pregnancies and Deliveries in Two Women With Chronic Myeloid Leukemia With Deep Molecular Response</b> <i>Popov VM, Voicu M, Marin I, Panait A, Andreescu M</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S551 <a href="https://doi.org/10.1016/S2152-2650(25)01905-6">https://doi.org/10.1016/S2152-2650(25)01905-6</a>	2.7	Q3	0	WOS:001606303900003
43	<b>Relapsed Primary CNS Diffuse Large B-Cell Lymphoma: A Case of Diagnostic and Therapeutic Complexity</b> <i>Pirvu E, Grasu D, Bacanu M, Vasile A, Malenda D, Andreescu M, Popov V</i> Clinical Lymphoma Myeloma and Leukemia, 2025; 25(Suppl 1): S756-S757 <a href="https://doi.org/10.1016/S2152-2650(25)02297-9">https://doi.org/10.1016/S2152-2650(25)02297-9</a>	2.7	Q3	0	WOS:001606311300069

## SECȚIUNEA D: Articole indexate PubMed (non-WOS) (6 articole)

(*Maedica* - a Journal of Clinical Medicine, indexata PubMed/PMC)

Nr.	Titlu / Autori / Jurnal	An
1	<b>Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders</b> <i>Tevet M (Andreescu M), Ionescu R, Dragan C, Lupu AR</i> <i>Maedica</i> , 2015; 10(1): 27-32. PMID: 26225146	2015
2	<b>2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes</b> <i>Michiels JJ, Tevet M (Andreescu M), Trifa A, Niculescu-Mizil E, Lupu A, Vladareanu AM, Bumbea H, et al.</i> <i>Maedica</i> , 2016; 11(1): 5-25. PMID: 28465746	2016
3	<b>Immunotherapy with Rituximab in Follicular Lymphomas</b> <i>Saguna C, Mut ID, Lupu AR, Tevet M (Andreescu M), Bumbea H, Dragan C</i> <i>Maedica</i> , 2011; 6(2): 100-105. PMID: 22205891	2011
4	<b>Secondary Acute Lymphoblastic Leukemia after Hodgkin Lymphoma or a Coincidental Association of Two Hematological Malignancies?</b> <i>Tevet M (Andreescu M), Dragan C, Saguna C, Barbu D, Lupu AR</i> <i>Maedica</i> , 2013; 8(4): 370-374. PMID: 24790671	2013
5	<b>New Molecular Markers in Diagnosis of Splenic Lymphomas</b> <i>Lupu AR, Closca-Gheorghiu M (Andreescu M), Ofiteru GC, Coles E, Ciocan O, Saguna C, et al.</i> <i>Maedica</i> , 2009; 4(1)	2009
6	<b>To Horizon: The Use of Synthetic O Blood Group in Practical Substitutive Therapy</b> <i>Lupu AR, Ciobanu A, Ciocan O, Closca-Gheorghiu M (Andreescu M), Saguna C, et al.</i> <i>Maedica</i> , 2007; 2(2): 130	2007

**SECȚIUNEA E: Articole publicate in reviste internationale non-WOS (8 articole)***(reviste Scopus, internationale, capitole de carte)*

Nr.	Titlu / Autori / Jurnal	An
1	<b>COVID-19-Associated Rhinocerebral Mucormycosis: An Increasingly Frequent Finding with Various Clinical Manifestations and Necessity for Critical Therapeutic Intervention</b> Andreescu M, Mocanu H, Mocanu AI, Moldovan C Medical Science: Trends and Innovations, 2025; Vol. 2: 70-100 (capitol de carte)	2025
2	<b>Recurrent Pregnancy Loss in Thrombophilia and Role of Anticoagulation Therapy: A Systematic Review</b> Andreescu M Perceptions in Reproductive Medicine, 2023; 5: 000618. DOI: 10.31031/PRM.2023.05.000618	2023
3	<b>Post-Polycythemia Vera Myelofibrosis (PPV-MF) - A Case Report of a Patient Transplanted after an Adverse Reaction to Covid Vaccination</b> Andreescu M, Tanase AD Annals of Case Reports, 2023; 8. DOI: 10.29011/2574-7754	2023
4	<b>Long Covid Case Report: Post SARS-CoV-2 Infection Evolution in Follicular Non-Hodgkin Malignant Lymphoma, under Monoclonal Anti-CD20 Antibodies Treatment</b> Andreescu M, Ilie N, Lacatusu A, Andrei TT, et al. Merit Research Journal of Medicine and Medical Sciences, 2023; 11(2): 040-044	2023
5	<b>Multimodality Imaging Can Shift the Clinical Approach and Prognosis of a Patient: From Heart Failure and Angina to Cardiac Amyloidosis</b> Chitroceanu AM, Nicula AI, Rimbas RC, Andreescu M, Popp C, Stoicescu C, Vinereanu D Romanian Journal of Cardiology (Scopus), 2022; 31(1): 102-110. DOI: 10.47803/rjc.2021.31.1.102	2022
6	<b>Bone Marrow Histology in CALR Mutated Thrombocythemia and Myelofibrosis</b> Michiels JJ, Kim Y, Kim M, et al., Andreescu M (Tevet M), et al. International Journal of Bone Marrow Research, 2019; 2(1): 064-078	2019
7	<b>Pathogenetic Mechanisms of Thrombosis in Patients with Myeloproliferative Neoplasm</b> Popov VM, Andreescu M, Vladareanu AM Hematology & Transfusion International Journal, 2018; 6(2): 51-54. DOI: 10.15406/htij.2018.06.00152	2018
8	<b>Laparoscopic Splenectomy - Optimal Solution in Autoimmune Thrombocytopenic Purpura</b> Mastalier B, Elaiah W, Deaconescu V, Gal-Penciu I, Tevet M (Andreescu M), et al. European Academic Research, 2015; 2(11): 565-570	2015

**SECȚIUNEA F: Articole in reviste nationale (21 articole)***(Oncolog-Hematolog, Romanian Journal of Medical Practice, Therapeutics Pharmacology, Revista Romana de Hematologie) Documenta Haematologica, Perceptions in Reproductive Medicine, Annals of Case Reports, Romanian Journal of Medical Practice, Oncolog-Hematolog, Therapeutics Pharmacology, etc.*

Nr.	Titlu / Autori / Revistă	An
<b>2025</b>		
1	<b>Evaluation of Ropeginterferon Treatment in Patients with Polycythemia Vera Grasu D, Popov VM, et al., Andreescu M (Indexat WOS 2025 - RC:142864070_S24)</b> Documenta Haematologica (Revista Română de Hematologie) <a href="https://doi.org/10.59854/dhrh.2025.3.1.39">https://doi.org/10.59854/dhrh.2025.3.1.39</a>	2025
2	<b>Caplacizumab in Recurrent Thrombotic Thrombocytopenic Purpura (TTP) Herdea MS, Ionescu AS, Patrinoiu O, Andreescu M (Indexat WOS 2025 - RC:124505829_S24)</b> Documenta Haematologica (Revista Română de Hematologie) <a href="https://doi.org/10.59854/dhrh.2025.3.1.49">https://doi.org/10.59854/dhrh.2025.3.1.49</a>	2025
<b>2024</b>		
3	<b>Herbal treatments for chronic rhinosinusitis - Western vs Eastern European traditional remedies Mocanu AI, Mocanu H, et al., Andreescu M, Nemes RM</b> Int J Modern Pharmaceutical Research <a href="https://ijmpronline.com/admin/assets/article_issue/1725099719.pdf">https://ijmpronline.com/admin/assets/article_issue/1725099719.pdf</a>	2024
4	<b>A comparative approach to classifications in AML diagnosis - WHO, ICC, ELN 2022 Omer M, Andreescu M, Popov VM, Vladareanu AM</b> Oncolog-Hematolog <a href="https://doi.org/10.26416/OnHe.66.1.2024.9389">10.26416/OnHe.66.1.2024.9389</a>	2024
5	<b>Secondary acute promyelocytic leukemia after breast carcinoma and multiple myeloma Omer M, et al., Andreescu M, et al.</b> Oncolog-Hematolog <a href="https://doi.org/10.26416/OnHe.69.4.2024.10352">10.26416/OnHe.69.4.2024.10352</a>	2024
<b>2023</b>		
6	<b>Recurrent Pregnancy Loss in Thrombophilia: A Systematic Review Andreescu M</b> Perceptions in Reproductive Medicine, 5(4): PRM.000618	2023

Nr.	Titlu / Autori / Revistă	An
7	<a href="https://crimsonpublishers.com/prm/pdf/PRM.000618.pdf">https://crimsonpublishers.com/prm/pdf/PRM.000618.pdf</a> <b>Post-Polycythemia Vera Myelofibrosis - Case Report of a Patient Transplanted after Covid Vaccination Adverse Reaction Andreescu M, Ilie N, Andrei TT, et al., Tanase AD</b> Annals of Case Reports, 8: 1182 DOI: <a href="https://doi.org/10.29011/2574-7754.101182">https://doi.org/10.29011/2574-7754.101182</a>	2023
8	<b>Long Covid Case Report: Post SARS-CoV-2 Infection Evolution in Follicular NHL under Anti-CD20 Treatment Andreescu M, Ilie N, et al., Popov V</b> Merit Research Journal / Zenodo, DOI: 10.5281/zenodo.7653420	2023
9	<b>Classic Hodgkin Lymphoma - mixed cellularity - case report and review of literature Oprea-Lebedenco M, et al., Andreescu M</b> Romanian Journal of Medical Practice, 18(1): 28-30 DOI: 10.37897/RJMP.2023.1.5	2023
<b>2021</b>		
10	<b>Lymphopenia: A predictive marker of disease severity in COVID-19 infection Georgescu GD, Balea M, Popov V, Andreescu M, et al.</b> Romanian Journal of Medical Practice, 16(4) DOI: 10.37897/RJMP.2021.4.18	2021
11	<b>Collaboration between Colentina Clinical Hospital and the transplant centers: A chance for life Georgescu GD, Mihai F, Omer M, Popov V, Andreescu M</b> Romanian Journal of Medical Practice, 16(2): 77 DOI: 10.37897/RJMP.2021.2.26	2021
12	<b>Multimodality imaging can shift clinical approach: from heart failure to cardiac amyloidosis Chitroceanu AM, Nicula AI, Rimbis RC, Andreescu M, Popp C</b> Romanian Journal of Cardiology, 31(1): 102-110 <a href="https://doi.org/10.47803/rjc.2021.31.1.102">https://doi.org/10.47803/rjc.2021.31.1.102</a>	2021
<b>2020</b>		
13	<b>Predictive value of hematologic and coagulation parameters in COVID-19 Popov VM, Iliescu L, et al., Andreescu M, et al.</b> Merit Research Journal of Medicine and Medical Sciences, 8(10): 605-615 DOI: 10.5281/zenodo.4140549	2020
<b>2015</b>		
14	<b>Treatment with hypomethylating agents in MDS and AML Georgescu D, Tevet M (Andreescu M), et al.</b> Therapeutics Pharmacology and Clinical Toxicology, XIX(2)	2015
15	<b>Acute myeloid leukemia in a 19-year-old patient treated for osteosarcoma - case report Dragan C, Murat M, Trifa A, Tevet M (Andreescu M)</b> Therapeutics Pharmacology and Clinical Toxicology, XIX(4): 165	2015
16	<b>Laparoscopic Splenectomy – Optimal Solution in Autoimmune Thrombocytopenic Purpura Mastalier B, et al., Tevet M (Andreescu M), Zurac S, et al.</b> European Academic Research (Int Multidisciplinary Research Journal)	2015
<b>2014</b>		
17	<b>Antiemetic therapy in hematologic and nonhematologic malignancies Georgescu DG, Popescu M, Tevet M (Andreescu M), et al.</b> Therapeutics Pharmacology and Clinical Toxicology, XVIII(3) <a href="https://therapeutics.ro/antiemetic-therapy-in-hematologic-and-nonhematologicmalignancies/">https://therapeutics.ro/antiemetic-therapy-in-hematologic-and-nonhematologicmalignancies/</a>	2014
18	<b>Assessment of prognostic factors in myelodysplastic syndromes Georgescu D, Tevet M (Andreescu M), et al.</b> Therapeutics Pharmacology and Clinical Toxicology, XVIII(2): 72-77	2014
19	<b>Terapia antiemetică în afecțiunile maligne hematologice și non-hematologice Georgescu DG, Popescu M, Tevet M (Andreescu M), Murat M, Nițea GR, Ciuhu AN</b> Oncolog-Hematolog / Therapeutics, Pharmacology and Clinical Toxicology, 2014; 18(3)	2014
<b>2013</b>		
20	<b>Remisiune completă la pacientă cu dublă neoplazie: limfom folicular și tumoră Grawitz Patrinoiu O, Georgescu D, Zurac S, Tevet M (Andreescu M)</b> Oncolog-Hematolog.ro Nr. 22 (1/2013).	2013
21	<b>Tratamentul cu Piperacilina/Tazobactam la pacienții neutropenici cu afecțiuni hematologice Andreescu M (Closca-Gheorghiu M) et al.</b> EMC Modul Endocrinologie <a href="https://arhiva.emcb.ro/article.php?story=20030112212449000">https://arhiva.emcb.ro/article.php?story=20030112212449000</a>	2003

**SECȚIUNEA G: Abstracte și postere la conferințe internaționale (92 lucrări)**

Conferințe internaționale majore: EHA, ASH, ISTH, SOHO/ICML, ISH, ISLH, ESHG, FEBS, etc. Ordonate descrescător după an.

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2025</b>			
1	PB2680 ANALYSIS OF UNFAVORABLE EVOLUTION FACTORS IN PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA. A SINGLE CENTRE EXPERIENCE Viola Maria Popov, Mirela Carmen Voicu, Anelis Panait, Iulia Marian, Diana Grasu, Elena Pirvu, .. Mihaela Andreescu	EHA Congress 2025, Milan	<b>2025</b>
2	PB3058 MARKERS OF INFLAMMATION, DISEASE PROGRESSION AND THEIR ASSOCIATION WITH NGS AND CHIP MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS: IMPLICATIONS FOR THERAPEUTIC DECISION-MAKING Laura Gabriela Tirlea, Sabina-Loredana-Georgiana Olteanu, Viola Popov, Mihaela Andreescu, ..	EHA Congress 2025, Milan	<b>2025</b>
3	PB3643 MULTIDRUG-RESISTANT INFECTIONS AND ICU ADMISSIONS IN HEMATOLOGIC PATIENTS: A SINGLE CENTER RETROSPECTIVE STUDY WITH TREND ANALYSIS ON CLINICAL RISK FACTORS Maria Cernat, Sabina Olteanu, Bianca Cristian, Viola Popov, .. Mihaela Andreescu	EHA Congress 2025, Milan	<b>2025</b>
4	PB3001 MISSED OPPORTUNITIES IN AL AMYLOIDOSIS: HOW E' VELOCITY, PERICARDIAL EFFUSION BIOMARKERS, AND DELAYED AMYLOID TYPING IMPACT ASTCT ELIGIBILITY Sabina Loredana Georgiana Olteanu, Laura Gabriela Tirlea, Viola Maria Popov, ..Mihaela Andreescu	EHA Congress 2025, Milan	<b>2025</b>
5	PB2548 IMPACT OF FLT3 MUTATIONS ON DIC PRESENTATION IN DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA Maria Bacanu, MEILIN OMER, VIOLA POPOV, DOINA POPA, ...MIHAELA ANDREESCU	EHA Congress 2025, Milan	<b>2025</b>
6	MCL-611: Complete Response in Refractory Mantle Cell Lymphoma After Bendamustine and Glofitamab Malenda AD, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606048700040)	IWCLL 2025	<b>2025</b>
7	MDS-961: MDS-RS Evolving From Hereditary Sideroblastic Anemia Cernat MR, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001605540100031)	IWCLL 2025	<b>2025</b>
8	IBCL-729: Clinical Challenges in Indolent NHL With Autoimmune Diseases Herdea MS, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001607063000093)	IWCLL 2025	<b>2025</b>
9	ALL-485: Simultaneous Acute Lymphoblastic Leukaemia and Renal Neoplasm Ionescu AS, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606305100040)	IWCLL 2025	<b>2025</b>
10	ABCL-701: CD20-Negative Double-Expressor DLBCL Grasu D, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606311300061)	IWCLL 2025	<b>2025</b>
11	CML-615: Sequential Multilineage Hematologic Malignancies Malenda AD, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606303900043)	IWCLL 2025	<b>2025</b>
12	MM-452: VEGF-Refractory Castleman-Variant POEMS Without Monoclonal Protein Olteanu SLG, et al., Popov V Clin Lymphoma Myeloma Leukemia (WOS:001606059100059)	IWCLL 2025	<b>2025</b>
13	MM-471: POEMS Syndrome in the Post-Pandemic Era - Romanian Center Experience Tirlea LG, Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606059100058)	IWCLL 2025	<b>2025</b>
14	CML-039: Successful Pregnancies in Two Women With CML With Deep Molecular Response Popov VM, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606303900003)	IWCLL 2025	<b>2025</b>
15	IBCL-182: When First Impressions Are Misleading: Imaging and Histopathology in Indolent Lymphoma Voicu MC, Popov VM, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001607063000059)	IWCLL 2025	<b>2025</b>
16	HL-699: Relapsed/Refractory Hodgkin Lymphoma Complicated by Pregnancy and Aspergillosis Grasu D, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001605514900078)	IWCLL 2025	<b>2025</b>
17	MCL-917: Ocular Adnexal Involvement in Mantle Cell Lymphoma Bacanu M, et al., Andreescu M Clin Lymphoma Myeloma Leukemia (WOS:001606048700047)	IWCLL 2025	<b>2025</b>
18	ABCL-761: Relapsed Primary CNS Diffuse Large B-Cell Lymphoma Pirvu E, et al., Andreescu M, Popov V Clin Lymphoma Myeloma Leukemia (WOS:001606311300069)	IWCLL 2025	<b>2025</b>
<b>2024</b>			

Nr.	Titlu / Autori / Publicare	Conferință	An
19	Evaluation of Prognostic Factors in Secondary Acute Leukemia Patients Omer M, Popov VM, Bumbea H, Andreescu M, et al. Blood, 2024; 144: 6141	ASH Annual Meeting	2024
20	A Primary Pulmonary Determination-A Rare Form of Marginal B-Cell Lymphoma Popov VM, Voicu M, et al., Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S221	ICML Congress	2024
21	Extramedullary Multiple Myeloma - Retroperitoneal Mass and Cholestatic Syndrome Popov VM, et al., Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S537	ICML Congress	2024
22	Complex Clonal Evolution in Advanced Myelofibrosis Bacanu M, Popov VM, et al., Andreescu M, Omer M Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S416	ICML Congress	2024
23	Particularities of Evolution in Acute Leukemia Patients With History of Neoplasms Omer M, Popov VM, Andreescu M, et al. Clinical Lymphoma Myeloma and Leukemia, 2024; 24: S319-S320	ICML Congress	2024
24	PB0069 - The assessment of the role of ROTEM in thrombosis risk evaluation of the severe form of COVID 19 patients Popov M. VM , Lelia Maria Iliescu, Mirela Voicu, Bogdan Mastalier, Mihaela Andreescu Poster	ISTH 2024 , Bangkok	2024
<b>2023</b>			
25	COVID-19-Trigger for Chronic Myeloid Leukemia Evolution? Popov V, Andreescu M Clinical Lymphoma Myeloma and Leukemia, 2023; 23: S333	ICML Congress	2023
26	Is COVID-19 a Trigger Factor for Thrombotic Complications in Late Pregnancy? Popov V, Mastalier B, Iliescu L, Andreescu M Research and Practice in Thrombosis and Haemostasis, 2023; 7: PO07	ISTH Congress	2023
<b>2022</b>			
27	The Assessment of Lymphopenia as Risk Factor for Unfavorable Evolution of COVID-19 Popov V, Iliescu L, Andreescu M, et al. HemaSphere, 6(Suppl): 1483-1484, P1602	27th EHA Congress, Vienna	2022
28	The Assessment of Predictive Role of Protein C and S for Critical Form of COVID-19 Popov V, Andreescu M, et al. HemaSphere, 6(Suppl): 1482-1483, P1601	27th EHA Congress, Vienna	2022
29	The importance of the long Covid-19 in the evolution of patients with neoplasms Popov V, Andreescu M, et al. Journal of Clinical Oncology, 2022; 40(16 suppl): e18647	ASCO Annual Meeting	2022
30	Is COVID-19 Infection a Trigger for Progression of CLL? Popov V, Bumbea H, Andreescu M, et al. Clinical Lymphoma Myeloma and Leukemia, 2022; 22: S140/S260	ICML Congress	2022
<b>2021</b>			
31	Survival analyses of COVID-19 in patients with hemato-oncological diseases in ICU Popov V, Iliescu L, et al., Andreescu M, Bumbea H American Journal of Hematology, 2021; 96(S2): S32	ASH/EHA Congress	2021
32	AML-168: Assessment of COVID-19 evolution in oncological patients in ICU Popov VM, Iliescu L, Andreescu M, et al. Clin Lymphoma Myeloma Leukemia, 21: S285-S286	LLMC Congress	2021
33	The Assessment of Thrombotic Complication in COVID-19 Patients Popov VM, Andreescu M, et al. Res Pract Thromb Haemost	RPTH Congress	2021
<b>2020</b>			
34	STUDY OF TREATMENT IMPACT ON PATIENTS WITH ATLS, SIRS AND MOD IN HEMATOLOGICAL MALIGNANCIES Andreescu M, Popov V, Georgescu D, et al., Tanase AD HemaSphere, PB187	25th EHA Congress (Virtual)	2020
35	Assessment of Hematologic and Coagulation Parameters in COVID-19 with Unfavourable Evolution Popov VM, Iliescu L, Georgescu DG, Andreescu M, Bumbea H Blood, 136(Suppl 1): 13	62nd ASH Annual Meeting (Virtual)	2020
36	Assessment of clinical evolution of COVID-19 and neoplastic malignancies patients Popov V, Andreescu M, et al. American Journal of Hematology, 2020; 95(S2): S26-S27	ASH/EHA Congress	2020
37	The Assessment of Platelet Membrane Alteration in Patients with MPN Popov V, Matei CO, Andreescu M, et al. Res Pract Thromb Haemost, 4(Suppl 1)	RPTH Congress	2020
38	The Prolonged Positivity of SARS-CoV-2 RNA in CLL Patients Popov V, Andreescu M, et al. Clin Lymphoma Myeloma Leukemia, 20: S228	SOHO Congress	2020
39	CT-365: Haematological and Biochemistry Parameters in COVID-19 as Predictive Factor Popov V, Iliescu L, Andreescu M, et al. Clin Lymphoma Myeloma Leukemia, 20: S217	SOHO Congress	2020
<b>2019</b>			
40	ASSESSMENT OF PLATELET MEMBRANE ALTERATION IN MYELOID METAPLASIA WITH MYELOFIBROSIS Popov V, Matei CO, Andreescu M, et al., Bumbea H HemaSphere, 3(S1): 984, PB2195	24th EHA Congress, Amsterdam	2019

Nr.	Titlu / Autori / Publicare	Conferință	An
41	CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OUTCOME IN AML PATIENTS OLDER THAN 60 Popov V, Georgescu D, Andreescu M, et al. HemaSphere, 3(S1): 808-809, PB1760	24th EHA Congress, Amsterdam	2019
42	Results from Treatment of a Large Cohort of ATL Patients from Romania Bumbea H, Marçais A, et al., Andreescu M, et al. Blood, 2019; 134(Suppl 1): 5288	ASH Annual Meeting	2019
<b>2018</b>			
43	EVALUATION OF THROMBOTIC RISK IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS Popov V, Andreescu M, Omer M, Trifa A, et al. HemaSphere, 2(S1), PB2311	23rd EHA Congress, Stockholm	2018
44	THE ROLE OF REACTIVE SPECIES PRODUCTION IN ASSESSMENT OF THROMBOTIC RISK IN MPN PATIENTS Popov V, Moisescu MG, Andreescu M, et al., Bumbea H Poster P-0159	25th Biennial International Congress on Thrombosis, Venice	2018
45	The Importance of CD36 Expression in Evaluation of Thrombotic Risk in MPN Popov VM, Omer M, Trifa AP, Andreescu M, Bumbea H Blood, 132(Suppl 1): 4989	60th ASH Annual Meeting, San Diego	2018
46	The fluidity of platelet membrane - an important parameter for platelet function in MPN patients Popov VM, Bumbea H, Savopol T, Andreescu M, et al. Poster PB041 (Reach the World Grant Award)	64th ISTH Meeting, Dublin	2018
47	The Importance of Fluorescence Anisotropy of Platelet Membrane in MPN Patients Popov V, Bumbea H, Andreescu M, et al., Moisescu MG Poster presentation	ESH International Conference on MPN, Dublin	2018
48	The evaluation of oxidative status and platelet membrane function in MPN patients Popov V, Matei CO, Andreescu M, et al., Bumbea H Poster No 290	XXXIst ISLH Symposium, Brussels	2018
49	The assessment of JAK2 mutation role in platelet membrane fluidity changes in MPN patients Popov VM, Matei CO, Trifa A, Andreescu M, et al., Bumbea H Poster presentation	XXXVII ISH World Congress, Vancouver	2018
<b>2017</b>			
50	The analyses of thrombotic risk in chronic myeloproliferative neoplasms patients Popov VM, Trifa A, Omer M, Andreescu M, et al. Poster P104	10th International MPN and CML Congress, New York	2017
51	Evaluation of Platelet Membrane Fluidity in Assessment of Thrombosis Risk in MPN Patients Popov VM, Matei MB, Andreescu M, et al., Bumbea H Poster P105	10th International MPN and CML Congress, New York	2017
52	The importance of platelet membrane fluidity and oxidative stress in thrombotic complications in MPN patients Popov VM, Andreescu M, Omer M, Trifa AP, et al. Haematologica, 102: 649-650, E-Poster E1602	22nd EHA Congress, Madrid	2017
53	Assessment of Changes of Membrane Properties and Platelets Function in CML Popov V, Vladareanu AM, Andreescu M, et al., Bumbea H Blood, 130(Suppl 1): 4846	59th ASH Annual Meeting, Atlanta	2017
54	Aggressive paraneoplastic encephalo-myelo-polyradiculoneuritis with anaplastic lymphoma Gaciu GC, et al., Andreescu M, et al. European Journal of Neurology, 2017; 24(Suppl S1): 440	EAN Congress	2017
55	Genomic abnormalities in acute myeloid leukemia with normal karyotype Arghir A, Papuc SM, et al., Andreescu M, et al., Bumbea H Molecular Cytogenetics, 2017; 10(Suppl 1): 23	ECA Conference	2017
<b>2016</b>			
56	THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES Popescu M, Georgescu D, Balea M, Tevet M, et al. Haematologica, 101: 871-872	21st EHA Congress, Copenhagen	2016
57	Hypereosinophilic syndromes FIP1L1/PDGFRΑ fusion gene NEGATIVE - hematological remission on imatinib Georgescu DG, Patrinoiu O, Popov V, Tevet M, et al. Br J Haematol, 173: 175-176	31st ISH Congress, Glasgow	2016
58	The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients Popov VM, Tevet M, Murat M, et al. Br J Haematol, 173: 129	31st ISH Congress, Glasgow	2016
59	Hematological malignancies in HIV/AIDS Georgescu DG, Tevet MT (Andreescu M), et al. British Journal of Haematology, 2016; 173(Suppl S1): 173-174	BSH Annual Meeting	2016
60	The importance of oxidative stress in abnormalities of platelet function in CML and MDS Popov V, Iordache M, Vladareanu AM, Tevet M, et al. Thromb Res, 141: S81	DLTH Congress, Istanbul	2016
61	Acute myeloid leukemia in a 19-year-old patient treated for osteosarcoma Dragan C, Murat M, Georgescu D, Tevet M (Andreescu M), Mihai F Bone Marrow Transplantation, 2016; 51: S599	EBMT Congress	2016
62	The role of JAK2 and CALR/MPL mutations in clinical evolution of MPN patients Popov VM, Tevet M, Mihai F, et al., Trifa A Poster presentation	ESH Conference for MPN, Estoril	2016
63	Recurrent and rare chromosomal abnormalities in acute leukemias – a 5 years study Papuc S, Bumbea H, Tevet M, Popov V, Andreescu M, et al., Arghir A EJHG, 24E-S1: 457, EP12.001	ESHG Conference, Barcelona	2016

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2015</b>			
64	The experience of a single center of hematology in the treatment with hypomethylating agents Georgescu D, Tevet M, et al. Poster presentation	13th MDS Symposium, Washington	2015
65	The experience of one Romanian center of hematology with hypomethylating agents Georgescu D, Tevet M, et al. Poster presentation	5th International Congress Lymphoma Myeloma, Istanbul	2015
66	Is membrane fluidity an important parameter in platelet function Popov VM, Vladareanu AM, Bumbea H, Tevet M, et al. Int J Lab Hem, 37(Suppl 2): 114	ISLH Conference, Chicago	2015
67	Study on Membrane Fluidity and medication influences in CML and MPN Popov VM, Iordache MM, Tevet M, et al. Poster presentation	National Biophysics Conference, Timișoara	2015
<b>2014</b>			
68	Second malignant tumors associated with hematological malignancies – frequency and significance Balea ML, Georgescu D, Tevet M, et al. Haematologica, Abstract PB1731	19th EHA Congress, Milano	2014
69	Evolution under treatment with VIDAZA in one case of RAEB-2 Georgescu D, Tevet M, et al. Poster presentation	4th International MDS Conference, Estoril	2014
70	Variation and distribution of mast cells in lymphoid lesions Cioplea MD, Zurac S, et al., Tevet M (Andreescu M), et al. Virchows Archiv, 2014; 465(Suppl 1): S278	ESP Congress	2014
<b>2013</b>			
71	Postsplenectomy evolution in one case of hypoplastic myelodysplastic syndrome Tevet M, et al. Poster presentation	12th International MDS Symposium, Berlin	2013
<b>2012</b>			
72	Clinical significance of JAK2 mutation in chronic MPN - hemorrhagic risk Tevet M (Andreescu M), Lupu AR, Saguna C, et al. Haematologica, 2012; 97(Suppl 1): 636	EHA Congress	2012
73	The role of JAK2-V617F mutation in leukemic transformation of MPN Tevet M (Andreescu M), Lupu AR, Saguna C, et al. Haematologica, 2012; 97(Suppl 1): 633	EHA Congress	2012
<b>2011</b>			
74	TREATMENT OF ELDERLY PATIENTS WITH AML WITH VALPROIC ACID AND LOW-DOSE MERCAPTOPYRINE Colita A, Lupu A, Closca M, et al. Haematologica	16th EHA Congress, London	2011
75	CHEMOTHERAPY WITH LOW-DOSE MERCAPTOPYRINE IN ELDERLY AML PATIENTS Colita A, Lupu A, Closca M, et al. Haematologica	16th EHA Congress, London	2011
76	PROGNOSTIC FACTORS IN FOLLICULAR LYMPHOMA: A SINGLE INSTITUTION STUDY Saguna C, Tevet M, Berbec N, et al. Haematologica	16th EHA Congress, London	2011
77	HODGKIN LYMPHOMA - PROGNOSIS AND EVOLUTION Ciocan O, Ciobanu A, Tevet M, et al. Haematologica	16th EHA Congress, London	2011
78	Myelodysplastic syndromes: challenging disorders for cytogeneticists Arghir A, Chirieac SM, Vladareanu AM, Closca M (Andreescu M), Bumbea H, et al. Chromosome Research, 2011; 19: S159-S160	ECA Conference	2011
<b>2010</b>			
79	FAVORABLE RESPONSE TO ALPHA-INTERFERON IN PEDIATRIC AGNOGENIC MYELOID METAPLASIA WITH FV LEIDEN Colita A, Arion C, Lupu A, Closca M, et al. Haematologica, 95: 1521	15th EHA Congress, Barcelona	2010
<b>2009</b>			
80	HODGKIN LYMPHOMA – PROGNOSIS AND EVOLUTION Ciocan O, Ciobanu A, Closca M, et al. Haematologica, 94(s2)	14th EHA Congress, Berlin	2009
81	NEW MOLECULAR MARKERS IN DIAGNOSIS OF SPLENIC LYMPHOMAS Closca-Gheorghiu M, Ofiteru G, Lupu AR, et al. Haematologica, 94(s2): 640-641	14th EHA Congress, Berlin	2009
82	FOLLICULAR LYMPHOMA: INCIDENCE, PROGNOSTIC FACTORS AND OVERALL SURVIVAL IN 78 PATIENTS (2002-2008) Saguna C, Closca M, Ciocan O, et al., Lupu AR Haematologica, 94(s2)	14th EHA Congress, Berlin	2009
83	PRIMARY B-CELL CUTANEOUS LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE Colita A, Lupu AR, Saguna C, Closca M, et al. Haematologica, 94: 1731	14th EHA Congress, Berlin	2009
<b>2008</b>			
84	AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) ASSOCIATED TO NON-HODGKIN'S LYMPHOMA (NHL) Colita A, Lupu AR, Angelescu S, Closca M, et al. Haematologica, 93(s1): 1383	13th EHA Congress, Copenhagen	2008
<b>2007</b>			
85	Apoptosis regulated protein levels and telomerase activity in high-grade NHL Goia CD, Closca M, Lupu AR, et al. Congress proceedings, p. 177	32nd FEBS Congress, Vienna	2007

Nr.	Titlu / Autori / Publicare	Conferință	An
86	Cytogenetic and molecular study of BCR/ABL negative chronic myeloproliferative disorders Hinescu ME, Arghir A, Closca M, Lupu A, et al. Chromosome Research, 15(1): 206	6th European Cytogenetics Conference, Istanbul	2007
<b>2006</b>			
87	Evolution of patients with essential thrombocytemia treated with Hydroxyurea and alpha-interferon Colita A, Lupu AR, Closca M, et al. Poster presentation	11th EHA Congress, Amsterdam	2006
<b>2003</b>			
88	T-cell ALL – Retrospective Study Lupu AR, Ciocan O, Alexa C, Closca-Gheorghiu M, et al. The Hematology Journal, Vol 4, Suppl 2	8th EHA Congress, Lyon, France	2003
89	Tuberculosis infection in acute leukemia – a report of 5 cases Lupu AR, Ciocan O, Closca-Gheorghiu M, et al. The Hematology Journal, Vol 4, Suppl 2	8th EHA Congress, Lyon, France	2003
<b>2002</b>			
90	PROGNOSIS FACTORS IN MYELOYDYSPLASTIC SYNDROMES Lupu A, Closca M Poster, The Hematology Journal, Vol 3, Suppl 1	7th EHA Annual Meeting, Florence	2002
91	The implication of hepatitis C virus in B-cells lymphoproliferative disorders Lupu A, Closca-Gheorghiu M, Ciocan O, et al. The Hematology Journal, Vol 3, Suppl 1	7th EHA Annual Meeting, Florence, Italy	2002
<b>2001</b>			
92	BIOLOGICAL IMMUNOPHENOTYPIC AND THERAPEUTICAL ASPECTS IN LYMPHOPLASMACYTOID LYMPHOMAS Lupu A, Alexa C, Closca M, et al. Poster, The Hematology Journal, Vol 1	6th EHA Annual Meeting, Frankfurt	2001

## SECȚIUNEA H: Abstracte și postere la conferințe naționale (24 lucrări)

Conferințele Societății Române de Hematologie (SRH), Societatea Română de Genetică Medicală (SRGM), etc.

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2025</b>			
1	Between cardiotoxicity and disease progression: Challenges in the management of relapsed FLT3-ITD AML Maria Bacanu, Meilin Omer, Mihaela Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
2	Risk stratification in chronic myeloid leukemia: clinical relevance of ELTS compared to Sokal and Hasford scores Diana Grasu, Elena Pirvu, Diana Malenda, Laura Tirlea, Sabina Olteanu, Raluca Cernat, Maria Bacanu, Mirela Voicu, Andreea Vasile, Viola Popov, Mihaela Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
3	From metastatic seminoma to secondary acute myeloid leukemia: a dual hemato-oncologic challenge Mihaela-Sabrina Herdea, Adela-Sara Ionescu, M.G. Zaidas, Andreea-Cristiana Vasile, Ana-Maria Petraru, Oana Patrinoiu, Mihaela Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
4	Race against time: acute myeloblastic leukemia, invasive fungal infection and transfusional inefficiency – a clinical case with unpredictable evolution Adela-Sara Ionescu, Mihaela-Sabrina Herdea, Geanina Carla Ofițeru, Mihaela Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
5	Acute myeloid leukemia with FLT3-ITD in an elderly patient: Prognostic implications and challenges in infection management B. Nistor, E. Pirvu, I. Marian, S. Herdea, S. Ionescu, G. Ofițeru, V. Popov, M. Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
6	Immune restoration in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors: data from a small center Ana-Maria Petraru, Diana Malenda, Mihaela-Sabrina Herdea, Diana Drăgoi-Cozmaciuc, Viola Popov, Mihaela Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
7	The gut microbiome in chronic myeloproliferative neoplasms: A synthesis of recent literature Laura-Gabriela Țirlea, Alina Daniela Tănase, Mihaela Andreescu Poster presentation	A XXXI-a Conferință Națională SRH	2025
8	Carfilzomib in relapsed multiple myeloma: response patterns in early biologic versus clinically aggressive relapse Mirela Carmen Voicu, Viola Maria Popov, Mihaela Andreescu, Diana Grasu Poster presentation	A XXXI-a Conferință Națională SRH	2025
9	Transfusional particularities in patients with multiple myeloma M.G. Zaidas, Andreea-Cristiana Vasile, Mihaela-Sabrina Herdea, Diana Grasu, Oana Patrinoiu, Mihaela Andreescu, Viola Popov Poster presentation	A XXXI-a Conferință Națională SRH	2025
<b>2018</b>			

Nr.	Titlu / Autori / Publicare	Conferință	An
10	CHROMOSOME 11 ANOMALIES IN ACUTE LEUKEMIAS Arghir A, Papuc SM, Popov V, Andreescu M, et al., Bumbă H Rev Rom Med Lab, 26(2) Suppl	2nd ARLM National Congress	2018
<b>2016</b>			
11	Structural anomalies of chromosome 11 in myeloid and lymphoid malignancies Arghir A, Papuc SM, Bumbă H, Tevet M, Popov V, et al. Volum simpozion	Simpozionul N. Cajal al ASM, București	2016
<b>2015</b>			
12	Chromosome 11 anomalies in acute leukemias Arghir A, Bumbă H, Tevet M, Popov V, Andreescu M, et al. Rom J Rare Diseases, S1/2015:25	7th SRGM Conference, Orăștie	2015
13	A case of acute lymphoblastic leukemia associated with acute pancreatitis at onset Mihai F, Dragan C, Tevet M, et al. Poster presentation	Conferința SRH, Sinaia	2015
14	The influence of oxidative stress on the platelet membrane among the patient with CGL Popov V, Georgescu D, Tevet M, et al. Poster presentation	Conferința SRH, Sinaia	2015
15	Alterations of platelet membrane functions among the patients with chronic MPN Popov V, Georgescu D, Tevet M, et al. Poster presentation	Conferința SRH, Sinaia	2015
16	The treatment with 5 AZACITIDINE in MDS and AML – practical aspects from Colentina Hospital Georgescu D, Patrinoiu O, Tevet M, et al. Poster presentation	Conferința SRH, Sinaia	2015
17	Evolution under treatment with TKI in one case of CML, blastic phase at onset Patrinoiu O, Popescu M, Tevet M, et al. Poster presentation	Conferința SRH, Sinaia	2015
18	Multiple Myeloma in young patients – clinical aspects, evolution and treatment challenges Murat M, Dragan C, Tevet M, et al. Documenta Haematologica Supplement-2015	Conferința SRH, Sinaia	2015
19	Concentration TNF alfa variation's significance in ET, JAK2+ and JAK2-, in ANAGRELIDE therapy Balea M, Ilea A, Tevet M, Popov V, et al. Poster presentation	Conferința SRH, Sinaia	2015
20	The result of molecular analysis to detect bcr-abl in lingual epithelium cells in Ph+ CML Balea M, Ilea A, Tevet M, Popov V, et al. Poster presentation	Conferința SRH, Sinaia	2015
21	Acute Myeloid Leukemia after Osteosarcoma in a 19 year old patient Dragan C, Murat M, Tevet M, et al. Poster presentation	Conferința SRH, Sinaia	2015
<b>2014</b>			
22	The frequency and pathogeny of renal disease in malignant hemopathies Balea ML, Tevet M, Georgescu D, et al. Poster presentation	Conferința SRH, Sinaia	2014
<b>2013</b>			
23	Case presentation: prognostic factors, classification, and risk models for OS prediction in MDS Tevet M, et al. Documenta Haematologica, XX(1-2)	Conferința SRH, Sinaia	2013
24	Diagnostic difficulties in acute leukemias Tevet M, Georgescu D, et al. Documenta Haematologica, XX(1-2)	Conferința SRH, Sinaia	2013

## SECȚIUNEA I: Prezentări orale la conferințe (70 prezentări)

### I.1. Prezentări orale la conferințe internaționale (10 prezentări)

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2025</b>			
1	Ce trebuie să știm despre coagulare în practica interdisciplinară? Conf. Dr. Mihaela Andreescu (speaker, moderator) Oral presentation	A VIII-a ediție a Conferinței cu Participare Internațională organizată de Facultatea de Medicină a Universității Titu Maiorescu din București	2025
2	Metastaze osoase cu origine necunoscută Conf. Dr. Mihaela Andreescu (speaker, moderator) Oral presentation	A VIII-a ediție a Conferinței cu Participare Internațională organizată de Facultatea de Medicină a Universității Titu Maiorescu din București	2025
3	Rolul Antifibrinoliticele și al factorilor de Coagulare Conf. Dr. Mihaela Andreescu (speaker, moderator) Oral presentation	A VIII-a ediție a Conferinței cu Participare Internațională organizată de Facultatea de Medicină a Universității Titu Maiorescu din București	2025
<b>2018</b>			
4	The analyses of influence of platelet membrane fluidity in platelet receptors expression in MPN patients Popov VM, Andreescu M, et al., Bumbă H Oral presentation	12 th WORLD HEMATOLOGISTS CONGRESS, London	2018
<b>2016</b>			
5	The Role of Bone Marrow Transplantation in the Case of Treatment Associated AML Dragan C, Tevet M, Georgescu D, et al. Poster presentation	ESH-EBMT 20 th Training Course on HSCT, Budapest	2016

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2015</b>			
6	TERT RS2736100 A>C AND JAK2 RS10974944 C>G POLYMORPHISMS IN MPN – MULTICENTRIC STUDY ON 500 PATIENTS Trifa AP, Tevet M, Popov V, et al. Oral presentation	SRGM Conference, Orăștie	<b>2015</b>
<b>2014</b>			
7	CML Treatment beyond the guidelines – country perspectives Tevet M (speaker) Oral presentation	3 rd CML Expert Summit, Lisbon	<b>2014</b>
8	Variation and distribution of mast cells in benign and malignant lymphoid lesions Cioplea MD, Zurac S, Tevet M, et al. Oral presentation, Virchows Archiv 465(S1):278	26 th European Congress of Pathology	<b>2014</b>
<b>2010</b>			
9	Exploring Molecular Mechanisms involved in Transformation of Hematopoietic Stem Cells in BCR-ABL Negative MPN Diaconu CC, Closca-Gheorghiu M (speaker) Oral presentation	INTERNATIONAL TRAINING COURSE, 2 nd ALUMNI CONFERENCE	<b>2010</b>
<b>2007</b>			
10	Apoptosis regulated protein levels and telomerase activity in high-grade non-Hodgkin's lymphomas Goia CD, Closca M (speaker), Lupu AR, et al. Oral presentation	32 nd FEBS Congress, Vienna	<b>2007</b>

## I.2. Prezentări orale la conferințe naționale (29 prezentări)

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2025</b>			
1	Diagnosis and management of 2 clinical cases with POEMS Syndrome Mihaela Andreescu Oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
2	Mantle Cell Lymphoma (MCL) – a paradigm for progress, BTKi drive practice change? Mihaela Andreescu, Mihnea Tudor Zdrengea Debate – oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
3	Rapid molecular diagnosis as standard of care in infections associated with acute myeloid leukemia patients M.R. Cernat, B.A. Cristian, P. Mihăilescu, A. Ipate, M. Andreescu Oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
4	Educational session: Anemia and iron deficiency – is there more to say? Optimizing iron treatment: from assessment to personalized therapeutic intervention Mihaela Andreescu (speaker), Moderator: Ioana Ioniță Oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
5	AstraZeneca Symposium: Paroxysmal Nocturnal Hemoglobinuria (PNH) – Pathology, Diagnosis, Management. PNH “at the crossroads” of intravascular hemolysis and thrombosis! Mihaela Andreescu (speaker, moderator) Oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
6	Angelini Symposium: Efficacy and Safety of Ponatinib in Patients with CML Mihaela Andreescu (speaker) Oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
7	Johnson & Johnson Symposium: First-line treatment in CLL – personalized approaches for all patient categories Horia Bumbea, Mihnea Zdrengea, Mihaela Andreescu, Catalin Dănăilă, Mariana Vasilică Oral presentation	A XXXI-a Conferință Națională SRH	<b>2025</b>
8	Abordarea multidisciplinară în patologia hematologică în diagnosticul HIV / HIV indicator conditions in hematologie Mihaela Andreescu (speaker) Oral presentation	Congresul Universității de Medicină și Farmacie Carol Davila din București	<b>2025</b>
9	Tromboza la intersecția specialităților Conf. Dr. Mihaela Andreescu (moderator), Conf. Dr. Cristina Mambet Oral presentation	A IX-a ediție a Conferinței Naționale a Societății Române de Hemostază și Tromboză	<b>2025</b>
10	HPN și interacțiunea între complement și sistemul hemostatic Conf. Dr. Mihaela Andreescu (speaker, moderator) Oral presentation	A IX-a ediție a Conferinței Naționale a Societății Române de Hemostază și Tromboză	<b>2025</b>
11	Lecții pandemice – hemostaza, inflamație, trombocitopenie și echilibrul fragil al răspunsului imun Conf. Dr. Mihaela Andreescu (speaker, moderator) Oral presentation	A IX-a ediție a Conferinței Naționale a Societății Române de Hemostază și Tromboză	<b>2025</b>
12	Abordarea integrativă a anemiei hemolitice și trombofiliei dobândite severe Conf. Dr. Mihaela Andreescu (speaker) Oral presentation	Congresul Național de Medicină Internă	<b>2025</b>
<b>2024</b>			
13	Sindrom POEMS – o provocare de diagnostic? Mihaela ANDREESCU (speaker) Oral presentation	A XII-a Conferință a Colegiului Medicilor din Municipiul București	<b>2024</b>
<b>2022</b>			
14	Mielomul multiplu – indicatori cheie pentru un diagnostic precoce Mihaela Andreescu (speaker) Oral presentation	Congresul Național de Medicina Internă	<b>2022</b>
<b>2021</b>			
15	Riscul trombotic legat de vaccinarea anti COVID Lector Univ. Dr. Mihaela ANDREESCU (speaker) Oral presentation	A VII-a Conferință Națională SRHT, București	<b>2021</b>

Nr.	Titlu / Autori / Publicare	Conferință	An
16	Sindrom antifosfolipidic în asocieri cu anomalia Leiden – management. Prezentare de caz Dr. Carmen ȘAGUNA, Dr. Mihaela ANDREESCU, Prof. Univ. Anca Roxana LUPU Oral presentation	A VII-a Conferință Națională SRHT, București	2021
17	Prima linie de tratament pentru pacientul eligibil pentru transplant Mihaela ANDREESCU (speaker) Oral presentation	A XXVII-a Conferință Națională SRH, Iași	2021
18	Prevenția și tratamentul neutropeniei și anemiei la mielom multiplu Mihaela Andreescu (speaker) Oral presentation	A XXVII-a Conferință Națională SRH, Iași	2021
<b>2019</b>			
19	Avortul recurent – punct de vedere al hematologului Mihaela Andreescu (speaker) Oral presentation	A VI-a Congresul Național al Societății de Hemostază și Tromboză	2019
20	Trombocitopenia, cheia în diagnosticul bolii Gaucher Popov VM, Balea M, Andreescu M, et al. Oral presentation	Conferința Colegiului Medicilor București	2019
<b>2017</b>			
21	Analiza modificărilor fluidității și potențialului de membrană trombocitară la pacienții cu neoplazii mieloproliferative cronice Popov V, Andreescu M, et al., Bumba H Oral presentation	A V-a Conferință Națională SRHT, București	2017
<b>2016</b>			
22	The role of Dexamethasone in the management of patients with Acute Myelogenous Leukemia Tevet M, Georgescu D, et al. (speaker) Oral presentation	Conferința SRH, Sinaia	2016
<b>2015</b>			
23	The Treatment with 5 AZACITIDINE in MDS and AML – Practical aspects from Colentina Hospital Georgescu D, Tevet M (speaker), et al. Oral presentation, Documenta Haematologica Supplement-2015	Conferința SRH, Sinaia	2015
24	The experience of a single Center of Hematology in the treatment with hypomethylating agents Georgescu D, Tevet M (speaker), et al. Oral presentation, Documenta Haematologica Supplement-2015	Conferința SRH, Sinaia	2015
25	Global burden and treatment outcomes of invasive pulmonary aspergillosis in hematological patients – case report Schiopu S, Popescu M, Tevet M (speaker), et al. Oral presentation, Documenta Haematologica Supplement-2015	Conferința SRH, Sinaia	2015
26	The management of acute leukemia – the experience of Colentina Hematology Department Popescu M, Tevet M (speaker), et al. Oral presentation, Documenta Haematologica Supplement-2015	Conferința SRH, Sinaia	2015
<b>2014</b>			
27	JAK2 V617F, CALR AND C-MPL MUTATIONS IN ET AND PMF – BIOLOGICAL AND CLINICAL CORRELATES IN 199 PATIENTS Trifa AP, Tevet M, Popov V, et al. Oral presentation	Congress of the Romanian Society of Medical Genetics, Bucharest	2014
<b>2010</b>			
28	MOLECULAR MARKERS IN BCR/ABL NEGATIVE MPN: FROM DETECTION TO SELECTIVE THERAPY Diaconu CC, Closca-Gheorghiu M (speaker), et al. Oral presentation	Academician N. Cajal Symposium, Bucharest	2010
29	CLINICAL PROGNOSIS AND ADJUSTMENT OF THERAPEUTIC MANAGEMENT RELATED TO JAK2 V617F MUTATIONAL STATUS IN Ph-NEGATIVE MPN Closca-Gheorghiu M (speaker) Oral presentation	Academician N. Cajal Symposium, Bucharest	2010

### I.3. Speaker invitat la simpozioane și workshop-uri (31 prezentări)

Nr.	Titlu / Autori / Publicare	Conferință	An
<b>2025</b>			
1	AB Kyprolis în secvențierea tratamentului la pacientul cu Mielom Multiplu Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
2	Particularitățile individualizării tratamentului la pacienții cu Mielom Multiplu și PTI Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
3	Efectul de restaurare imună în urma tratamentului cu Ibrutinib atât ca terapie continuă, cât și durată fixă (I+V) la pacienții cu LLC Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
4	Profiluri de pacienți tratați cu Darzalex + Rd (lenalidomidă+dexametazonă) pentru pacienții ineligibili pentru transplant Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
5	Discuție despre experiența globală transpusă în experiența proprie cu Imbruvica. Împărtășirea experienței proprii cu Imbruvica în gestionarea diferitelor profile de pacienți cu LLC, importanța alegerii primei opțiuni de tratament eficiente pentru pacienții cu LLC, ținând cont de status mutațional și cel de fitness, cu scopul de a le crește durata de supraviețuire, importanța menținerii aderenței pe termen lung. Mihaela Andreescu (speaker) Oral presentation	Workshop	2025

Nr.	Titlu / Autori / Publicare	Conferință	An
6	Why Imbruvica and venetoclax can be the best treatment option for different patient profiles Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
7	Patologie LMC + Scemblix Singurul Inhibitor la nivelul buzurarului miristoil al BCR-ABL1 Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
8	Hemoglobinuria paroxistică Nocturnă – urgență medicală și abordări terapeutice Mihaela Andreescu (speaker), Viola Popov Oral presentation	Workshop	2025
9	How I Treat Front Line Multiple Myeloma in 2025 and Treatment Selection at Relapse for Optimal Sequencing: A clinician perspective: Clinical causes Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
10	Optimizing Iron Supplementation: Clinical Algorithms, Indications, and Regimens Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
11	Empowering Innovations: Changing the Landscape of CLL treatment Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
12	Impactează scorul prognostic alegerea I. TK? Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
13	Amiloidoza sistemică cu lanțuri ușoare: Provocări de diagnostic și tratament Mihaela Andreescu (speaker) Oral presentation	Workshop	2025
<b>2024</b>			
14	Current landscape of PV therapy: Personalized treatment approaches (SIMPOZION NOVARTIS) Mihaela ANDREESCU (moderator) Oral presentation	A XXX-a Conferință Națională SRH, Sinaia	2024
15	B-cell line treatment sequencing in DLBCL: from 1 st L to 3 rd L+ (SIMPOZION ROCHE) Mihaela ANDREESCU (speaker) Oral presentation	A XXX-a Conferință Națională SRH, Sinaia	2024
16	Advances in the treatment of L3+ DLBCL with Tepkinly® (SIMPOZION ABBVIE) Mihaela ANDREESCU (speaker) Oral presentation	A XXX-a Conferință Națională SRH, Sinaia	2024
17	DAURISMO® (glasdegib): Improving response in patients with difficult-to-treat AML (SIMPOZION PFIZER) Mihaela ANDREESCU (speaker) Oral presentation	A XXX-a Conferință Națională SRH, Sinaia	2024
18	Why would Calquence be a preferred option for young patients with CLL and comorbidities (SIMPOZION ASTRAZENECA) Mihaela ANDREESCU (speaker) Oral presentation	A XXX-a Conferință Națională SRH, Sinaia	2024
19	N-plate – abordarea clinică a tratamentului pe termen lung la pacientul cu PTI Mihaela ANDREESCU (speaker) Oral presentation	Workshop	2024
20	ITP – ask the experts – Cum tratăm PTI în România Mihaela Andreescu (speaker) Oral presentation	Workshop	2024
21	When should we choose BESREMi for patients with polycythemia vera? Guidelines updates for PV and clinical experience Mihaela Andreescu (speaker) Oral presentation	Workshop	2024
22	Caz clinic: Limfom cu Celulă Mare B Mihaela Andreescu (speaker) Oral presentation	Workshop	2024
23	Jakavi PV – Soluția eficientă la pacientul cu risc crescut care este rezistent/intolerant la hidroxiuree Mihaela Andreescu (speaker) Oral presentation	Workshop	2024
<b>2023</b>			
24	Suntem arhitecții viitorului liber de boală și de tratament (SIMPOZION ABBVIE) Mariana Vasiliță, Mihaela ANDREESCU, Mihaela Lăzăroi, Horia Bumbea, Cătălin Dănăilă Oral presentation	A XXIX-a Conferință Națională SRH, Iași	2023
25	Imbruvica+venetoclax: pentru că viața este obiectivul suprem (SIMPOZION JANSSEN) Mihaela ANDREESCU (speaker) Oral presentation	A XXIX-a Conferință Națională SRH, Iași	2023
26	MYLOTARG® (gemtuzumab ozogamicin) – Esențial în tratamentul de primă intenție al LAM (SIMPOZION PFIZER) Mihaela ANDREESCU (speaker) Oral presentation	A XXIX-a Conferință Națională SRH, Iași	2023
27	Kyprolis în tratamentul mielomului – de la teorie la practică Mihaela ANDREESCU (speaker) Oral presentation	Masă rotundă – Amgen	2023
<b>2022</b>			
28	Blinicyto: Importanța diagnostic MRD: de la teorie la practică Mihaela Andreescu (speaker) Oral presentation	Webinar Amgen	2022
<b>2021</b>			
29	Kyprolis: Șanse ani de supraviețuire GLOBALĂ contează! Mihaela Andreescu (speaker) Oral presentation	Webinar Amgen	2021
<b>2019</b>			
30	Kyprolis: Supraviețuirea generală contează, experiența clinică la pacientul cu Mielom Multiplu Mihaela ANDREESCU (speaker) Oral presentation	Masă rotundă – Amgen	2019
<b>0</b>			
31	GP Imbruvica – Imbruvica LLC, LCM, MW – Preluați controlul bolii Mihaela Andreescu (speaker) Oral presentation	Eveniment Johnson & Johnson	0

## G. CĂRȚI PUBLICATE

Nr.	Titlu / Autori / Editura	ISBN	An	Rol
1	<b>Terapie regenerativă cu celule stem</b> Andrescu M, Tanase AD <i>Editura Hamangiu</i>	978-606-27-2330-9	2023	Autor principal
2	<b>Regenerative Therapy with Stem Cells (English edition)</b> Andrescu M, Tanase AD, Cosmin Moldovan <i>Editura Hamangiu</i>	978-606-27-2479-5	2024	Autor principal
3	<b>Bioetică și Deontologie medicală. Avatarul unui ideal</b> Andrescu M, Andrei TT <i>Editura Universității Titu Maiorescu</i>	978-606-767-108-7	2023	Autor principal
4	<b>Avortul recurent</b> Andrescu M <i>Editura Amaltea</i>	978-973-162-201-9	2019	Autor unic
5	<b>Hematologia în practica medicală</b> Lupu AR (coord.), Ciocan O, Ciobanu A, Closca-Gheorghiu M (Andrescu M), Bleotu L, Ciufu C <i>Editura Carol Davila București</i>	-	2005	Co-autor

Șp. 01. 2026.

